Nanobiotech pioneers
Nanobiotech
pioneers
There are several
organizations that have been active in India. BioSpectrum presents the
activities of some of them here.
NCRM
Chennai-based Nichi-In Centre for Regenerative Medicine (NCRM) has been
working on close to 240 different nanomaterials and technologies in
specialties such as ophthalmology (corneal regeneration), orthopedics
(cartilage injury repair), and hematology (expansion of hematopoietic
stem cells).
Virtus
Technoinnovation
Mumbai-based Virtus Technoinnovation Pvt Ltd works on the science of
gene repair therapy which CEO, Dr Tripathi terms as biomimicry. Its
research team at present is working on a technique which will slacken
the pace of the aging process in a human being. “Ongoing
research is done in the field of biomimicry by topically using
nanoparticles of the 92 trace minerals and the 28 amino acids. We call
it we are mimicking the ‘gene-repair-experience’ of
the fetus floating in the amniotic fluid in the mothers womb. The fluid
contains nanoparticles of the same minerals etc. in organic form. The
inactive genes of the fetus received from parents at procreation age
are being ‘in vivo repaired’ in the
mother’s womb,” said Dr Tripathi. Despite this
being known to science for past few decades, Dr Tripathi claims, that
he is the first scientist to study the receptors under the skin of the
fetus carrying the minerals to the gene-proteins. “The
contention here is that the human genome which is responsible for the
whole process of aging remains active at birth but then by the time we
reach the age of 25 years, 90 per cent of them become
silent,” said Dr Tripathi.
Tata
Chemicals
Pune-based Tata Chemicals Ltd (TCL) is also working on
nanotech-based products that are still some distance away from
commercialization but was reluctant to give out details. “The
main research in TCL is around nanotech and biotech based products and
processes,” was the only statement that was brought out.
Similar is the case with RLS. The company at present does not have any
product offering in nanotechnology but is researching on
delivery systems using nanotechnology
Nanomedicine, that involves drug particles engineered to the size of an
atom, is at the frontline of new drug delivery. It is playing a key
role in life cycle management of existing drugs, where novel
formulations based on nanomaterials are enhancing bioavailability and
efficacy, and reducing side effects. A number of Indian pharma and
biotech companies are working on the applications of nanotech in drug
delivery.
Dabur
Research Foundation
Dabur Research Foundation last year launched the indigenously developed
nanoparticle paclitaxel formulation, Nanoxel. Speaking about this
product, Dr Surendra Tyagi of Dabur said, “Our Nanoxel is the
only nanomedicine approved and launched outside US. It
demonstrates improved efficacy and significantly lesser toxicity
compared to the conventional paclitaxel
formulations.” It has also been launched in
Philippines and we are planning to expand the availability of this
product for many more countries including US and EU countries, he
added. Dabur Research Foundation has a promising pipeline of other
oncology products based on similar drug delivery system.
Lifecare
Innovations
Gurgaon-based Lifecare Innovations is yet another company that
specializes in controlled release of pharmaceuticals by employing an
array of technologies of novel drug delivery systems (NDDS). The
company which was started in 2000 has been the first of its kind to
combine liposome technology with nanotechnology for liposome mediated
delivery of Amphotericin B through its breakthrough product
Fungisome. “Fungisome is an undisputed drug of
choice for the treatment of dreaded mucor mycosis which is alarmingly
on the rise in India due to indiscriminate use of other anti-fungals in
spite of well established knowledge that no other anti-fungal drug is
effective in patients of mucor mycosis. We took the laboratory scale
technology of DBT and we complemented it with nanosomisation to make
nanosomes of liposomal Amphotericin B,” said Dr JN Verma, MD,
Lifecare Innovations. Taking the technology a bit further, the company
then developed a liposomal dithranol for the treatment of psoriasis.
Today Lifecare Innovations has platform technologies for oral and
parenteral sustained released nanodrugs. “Using that
technology we have developed an anti-TB formulation in collaboration
with PGI-Chandigarh. Preclinical toxicology work is over and we are
starting clinical trials soon,” added Dr Verma. The company
is also working on other oral sustained release nano-drugs for variety
of treatments with institutions in South Africa, Brazil and Canada.
Velbionanotech
Bangalore-based Velbionanotech (VBN) developed a bionanochip which
functions in targeting and cure for nephrolithiasis in a disease
specific and controlled mechanism of nanomedicine release. Bionanochips
can be injected into the blood stream, they circulate and reach
kidneys. The bionanochip senses the decreased pH in the environment
around the stone and identifies the site for functioning. The decreased
pH in the vicinity of the stone triggers the release of the
nanomedicine from the VBN bionanochip. The released nanomedicine then
function on the stones leading to their removal. The nanochip thus
functions with a hallmark of mechanism of disease specific targeting
and release of nanomedicine in a controlled mechanism.
The company has invested around $10 million on nanobiotechnology
through private equity funding. Speaking about his company’s
research activities Joseph Asantraj, CEO, Velbionanotech said,
“We are currently working on nephrolithiasis, diabetes
mellitus and atherosclerosis. Our focus for next nanotechnology
products will be on neurological disorders.” We have recently
started our research for neurological disorder and we are also planning
to come out with Nanodevices which is still under paper work, he added.
Agharkar
Research Institute
Pune-based Agharkar Research Institute (an autonomous institute of the
Department of Science and Technology, Government of India) is a pioneer
in the field of nanobiotechnology. For the past nine years, its focus
is on the applications of nanotechnology in medicine, environment and
agriculture. The institute has a strategic tie-up with a start-up
company, Nano Cutting Edge Technology Pvt Ltd (Nanocet) floated by
Khandelwal Laboratories, Mumbai. Agharkar Research Institute has
licensed several patents to Nanocet. In addition, Nanocet has been
funding research at the institute for the past three years. The
institute has also given a nanotechnology incubator facility to Nanocet
in its premises provided expertise to the company on the path to
commercialization of the technologies. Talking about this
research-industry partnership, Dr Kishore M Paknikar, in-charge, Center
for Nanobioscience, Agharkar Research Institute, said, “This
arrangement has proved very useful. Recently, the Drug Controller
General of India (DCGA) has granted permission to Khandelwal
Laboratories for the manufacture of ‘Nanocrystalline silver
gel’ for the treatment of burns and wound infections. The gel
contains silver nanoparticles made by our patented process that work as
a potent antimicrobial agent. This is perhaps the first product of its
kind being approved in India. The gel will be available in the Indian
market shortly.”
Jahanara Parveen with
Nayantara Som and Shalini Gupta